Comparative Pharmacology
Head-to-head clinical analysis: FELBATOL versus PHENURONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FELBATOL versus PHENURONE.
FELBATOL vs PHENURONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Felbamate is a GABA receptor agonist and modulates NMDA receptor activity, though its exact mechanism is not fully understood. It appears to enhance GABA-mediated inhibition and inhibit voltage-gated sodium channels, reducing neuronal excitability.
Phenurone (phenacemide) is an anticonvulsant that reduces neuronal excitability by inhibiting voltage-gated sodium channels and potentiating GABAergic inhibition. It also has a structure similar to other hydantoins and may increase the seizure threshold.
1200-3600 mg/day orally in 3-4 divided doses; initial titration recommended.
Adults: 500 mg to 1 g orally twice daily, increased gradually up to 3 g/day in divided doses.
None Documented
None Documented
20-23 hours; steady state reached within 3-5 days; may be prolonged in hepatic impairment.
The terminal elimination half-life is approximately 22-35 hours in adults. This long half-life supports once- or twice-daily dosing, but requires careful monitoring for accumulation.
Renal: 40-50% unchanged; Hepatic metabolism accounts for ~50% with glucuronidation and oxidation; minimal biliary/fecal excretion (<5%).
Phenurone is extensively metabolized in the liver; less than 1% is excreted unchanged in urine. The primary metabolite is 4-hydroxyphenylethylhydantoin (p-HPEH). Renal excretion accounts for approximately 70-80% of the dose, mainly as metabolites; the remainder is eliminated via bile/feces. Enterohepatic circulation may occur.
Category C
Category C
Anticonvulsant
Anticonvulsant